Loading
A phase 3 trial of Daratumumab, Dexamethasone and Pomalidomide in multiple myeloma, run by Biocad, now recruiting.
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) is a phase 3 interventional study registered as NCT07742215 by Biocad, with 390 participants planned, started 2026-06-15 and due to reach its primary completion in 2028-07. Interventions recorded: BCD-248 + daratumumab and Daratumumab + pomalidomide + dexamethasone.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Biocad, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies and the tag pipeline.
Shares Pomalidomide, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Daratumumab, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Biocad, Monoclonal antibodies and the tag pipeline.
Shares Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/